Immunoglobulin classes G,A,M in brain tumours (original) (raw)
Related papers
Serum and CSF immunoglobulins G, A and M in 37 intracranial tumors
JPMA. The Journal of the Pakistan Medical Association, 2002
To estimate different proteins and immunoglobulins as humoral immune response in patients with intracranial tumours. Cellulose acetate membrane electrophoresis for estimation of different proteins and radialimmunodiffusion (RID) for measurement of serum and CSF immunoglobulins were used. Thirty seven patients with different types of tumours showed increase in serum alpha II globulin, significant decrease of IgG, in patients when compared with controls, significant decrease of IgG in malignant tumours compared with benign tumours. CSF albumin, gamma globulin, immunoglobulins G,A,and M were increased. Alpha II globulin, steroid therapy and active neoplasia may be responsible for decreased serum immunoglobulins, while raised gamma globulin and immunoglobulins with intact BBB indicates capability of CNS to produce immunoglobulins.
Immunological monitoring of brain tumour patients
International Surgery Journal, 2018
Background: Patient suffering from CNS tumours are among the best suited as regards the study of their immunologic status is concerned because these tumours rarely metastasize and general condition of patient is not much affected. Extensive research has been done on immunological response in neoplasms of other organs, but immunology of CNS tumours studied mainly during last five decades. It is now realized that immunologic reactions may be important in the development and growth of the CNS tumours. Although there is evidence that immunotherapy is helpful in control of some solid tumours but adequate knowledge of the immunology of glial tumours to guide the rational treatment is not yet available. Methods: This study was conducted on 60 cases that included 20 controls and 40 patients of primary intracranial brain tumors admitted to neurosurgical services of University Hospital, Banaras Hindu University, Varanasi during the period of January 1987 to January 1988. Results: The study r...
Journal of Neuroimmunology, 2010
Aim: To investigate the cellular and humoral immunity status of gliomas, and their association with the WHO grading system. Material and methods: We have conducted a case-control study of 49 patients with gliomas and 30 healthy controls. We used ELISA assays, radial immunodiffusion, indirect immunofluorescence, latex test and flow cytometry assays to estimate preoperative in serum the immunological profile. Results: Patients with glioma had significantly reduced amounts of IL2 (p = 0.000), TNF-a (p = 0.033), IgG (p = 0.011), IgA (p = 0.027),C4 (p = 0.026) ,CD3+ (p = 0.001), CD4+ (p = 0.000), CD8+ (p = 0.002), ratio CD4/CD8 (p = 0.000), CD19+ (p = 0.04) and elevated IL10 (p = 0.05) compared with healthy controls. No statistically significant differences were observed concerning viral agents, total NK cells, IgM, IgE, IL16, granzyme-b, RF, ANA, ENA, anti-dsDNA and anti-cardiolipin antibodies. A higher WHO grade, after controlling for age and gender, was associated with decreased number of CD3+ (p = 0.011), CD4+ (p = 0.015), CD8+ (p = 0.048) and ratio CD4/CD8 (p = 0.027), as well as with decreased IL2 (p = 0.018), C4 (p = 0.02), and IgG (p = 0.05). IL2 and CD4+ counts were significant predictors of grade. Conclusions: A shift from Th1 to Th2, a CD3+ and CD19+ lymphocytopenia, a diminished fraction CD4/CD8 and a reduced amount of immunoglobulins and complement were observed in the patients with gliomas. A higher WHO grade of the tumor was associated with greater impairments of immunity. Since defects of both humoral and cellular immunity were equally observed and significant predictors of grade were assessed, a preoperative evaluation of the immune system of patients with gliomas is being proposed.
Immunologic status in children with brain tumors and the effect of therapy
Journal of Neuro-oncology, 1995
Summary The cellular and humoral immunological parameters (leucocyte, granulocyte, lymphocyte, total T, T4, T8 lymphocyte counts, lymphoproliferative response to PHA [LP-PHA), natural killer cell activity [NKCA], IgG, IgM and Ig A levels) of 20 pediatric brain tumor patients were investigated before and after chemo-(CT) and radiotherapy (RT) administered according to the UIOI-PBT-91 protocol. The T4 and T8 cell percentages and
Serum IgE levels in patients with intracranial tumors
Neuroimmunology and Neuroinflammation, 2015
Aim: Several epidemiological studies have shown an inverse correlation between allergy and brain cancer. The purpose of this study was to compare the serum IgE levels between patients with gliomas and nonglial tumors and their possible prognostic role. Methods: A total of 84 patients with intracranial tumors were included in this study. At clinical presentation, estimation of serum IgE levels was assessed by nephelometry. Detailed information regarding the history of allergies was collected by interview. Results: Of the 84 cases, 42 were gliomas, 23 were meningiomas, 16 were metastases and 3 were primary central nervous system lymphomas. Patients with high-grade glioma had lower IgE levels than patients with low-grade glioma. Patients with glioma and meningioma had statistical significant lower serum IgE levels than patients with metastases. Patients with glioblastoma with serum IgE levels greater than 24 U/mL had a better survival. Conclusion: Patients with glioma and meningioma had lower IgE levels than patients with metastatic lesions. A prognostic role of serum IgE levels was found in glioblastoma. Further studies in larger patient series are required in order to verify our preliminary observations.
Immunobiology of primary intracranial tumors
Journal of Neurosurgery, 1981
Levamisole was evaluated as an immune stimulant in a randomized controlled study of patients with anaplastic gliomas, who had undergone surgical resection and who were also treated with radiotherapy and BCNU chemotherapy. Of 102 patients placed into the study, 85 were determined to comprise the adequately treated group (ATG): a full course of radiotherapy and two cycles of BCNU chemotherapy. Within the ATG, those patients who received levamisole did not demonstrate significantly different serial delayed hypersensitivity reactions, peripheral blood lymphocyte and T-cell counts, or serum IgM levels, compared to those patients not receiving levamisole. There was no significant difference in survival times of the two groups. Studies utilizing the avian sarcoma virus-induced glioma in rats also showed no improvement in survival with levamisole stimulation as the only immune agent, but the combination of active immunization and adjuvant stimulation with bacillus Calmette-Guerin plus levamisole was found to be therapeutically effective in this model and will be used in future pilot studies of active immunization in patients. KEY WORDS 9 levamisole immunostimulation 9 malignant glioma therapy 9 glioma model 9 radiotherapy 9 BCNU chemotherapy *Phipps strain BCG from the Trudeau Institute Mycobacterial Culture Collection was kindly supplied by Dr. Herbert J. Rapp of the National Cancer Institute.
An immunohistological study of the presence of inflammatory cells in malignant brain tumors
2013
The purpose of this study is to appreciate if there is an immune response in malignant brain tumors. Material and methods: Eleven astrocytomas of varying histological features were immunohistologically studied, using a panel of monoclonal antibody against CD20cy to highlight T-lymphocytes, CD3 for B-lymphocytes and CD68 as marker of the macrophages. Ki67 antibody was used as marker of proliferation. We evaluated the presence of these markers in peritumoral stroma and intratumoral tissue. Results: In our study, none of the astrocytic tumors studied showed B-lymphocytes. The presence of T lymphocytes was evidenced in all 11 selected cases. While low-grade astrocytomas showed positive CD3 immunostaining only in tumoral cells, anaplastic astrocytomas and glioblastomas revealed positive immunostaining also in perivascular space. As it was expected, mean values for proliferative marker Ki-67 revealed that there was a significant difference between the indices of low(grade II) and high-gra...
Cancer, 1983
The responsiveness of lymphocytes obtained from patients with brain tumors to in vitro stimulation with mitogenic lectins was examined. The previously reported finding of decreased responsiveness was confirmed. To investigate the factors responsible for the hyporesponsiveness, mitogen (phytohemagglutinin and pokeweed mitogen) induced lymphocyte activation was evaluated using lymphocytes from 22 patients with brain tumors and 22 normal individuals. Lymphocytes from 13 patients with brain tumors, showed depressed responsiveness when cultured in autologous serum; in eight this was marked and in five moderate. Normal, rather than autologous, serum corrected lymphocyte function from only one of the markedly hyporesponsive patients, suggesting the existence of an intrinsic lymphocyte abnormality in some patients with brain tumors. However, serum from the hyporesponsive patients depressed mitogen-induced activation of lymphocytes from both tumor patients and normals. The presence of suppressive serum factors could not be related to the nature of the tumor (benign versus malignant, site, cell type or degree of anaplasia). The present studies showed that significant depression of in v i m lymphocyte responsiveness occurred with exposure to two anti-convulsant agents (phenytoin and phenobarbital) and dexamethasone. Thus, impaired lymphocyte function in patients with brain tumors may have a complex explanation with drug (corticosteroids, anticonvulsants) induced suppression playing a significant role. Cancer 51:248-255. 1983. EVERAL RECENT STUDIES have demonstrated im-S paired cell mediated immunity in patients with brain tumors.'-9 This impaired responsiveness has been identified by skin test anergy to a variety of antigens. a decrease in the number of T-cells in the circulating lymphocyte population or by decreased in vitro responsiveness of lymphocytes to mitogens or antigens. Thus, Brooks el al. ' studied 23 patients with a variety of benign and malignant intracranial tumors, and observed 1 I
Long-term immunological investigation of malignant intracranial gliomas
Surgical Neurology, 1981
In ihi* ~tudy, 118 cor~,~:~tive adult lemients with supralenmriM Rliomas undrr~ent Vr¢o~:ra6vv im-munol~deal monitoring, with particular regard to B-Iym#ocy|e arid T-|ymph~yte marker--, MOst patlcnt., were treated suvMrall}" a~d whh r~dh)thceapg, ~lree month~ bier, they were rradmim.d fi-,r ~t~.~+rative im-munolo#eM inve:ligation ar~J {d|oiv.up control A IOta| of 76 ras¢~ could thus ~ complctelg in~'e.~filaaled and urre stalls||rally di#hle foe evahatation, A pronounced i;,ilure o{ T+cel~mediatrd immunity was observed: "E+activc" rose~te-fo~ming cells and milo~en+inducrd bta,~o~etm~i.~ testx tum~ ~ui to be mark¢dly drprcs.~,-'d+ with a s|ight r~,¢or~rat~-¢ recovery+ Spo~tanc~o~ re|l-mediated ¢ylo* to,icily war. sigltificant|y ~p < 0.01) inctca~+:d both in preoptaratlve and F~st,)pera|i+,e findinl~+ TRy mat= immunodia[.mostic t-,atterft.~ (immurtog|oba tins a s~av+ :,o ~acc immun~lnbulin+-, "mou~e '+ r,a.,,elte:,| ¢,.,nOert~ln~ the B+ cell+dependent "Ix,hi +' were found to Ix+ ~dthin norma| }imits, G~t+.++-a M N.~.~+++:..au+ ++ +*+ A~+~*. £+?+ ++ + Oh+++ A+ R,.++th++ A+ Z+~+c¢++++. ' :ih, ++' ,L h.,+,c+ t.i+ l +++¢++++. +m+ m:+ IIIU++O~i~+(++} ++IpC~t+|~++I++I+ ~+ mahOi+++++~ +I++++ tcfa++~,+~ Chorea+.. S~+t~ Neutol |O aS+ 52, 1!+8t v+mf~ ++. y. +. I++. m {(.+TN+S) }lave ~+el'~ t~:Fu+)lled t+~ :,how V+ part~¢lilar dcp~ex<o~ ~f ce||-:n,ediated immum~y {2+ 4+ 9+ t L 18. 2i.